RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
August 30, 2026
The FDA granted the approval of Revolution Medicines’ daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.